Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets cut its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 91.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,819 shares of the medical device company's stock after selling 268,768 shares during the period. BNP Paribas Financial Markets' holdings in Tandem Diabetes Care were worth $894,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Park Avenue Securities LLC raised its position in shares of Tandem Diabetes Care by 34.5% during the 4th quarter. Park Avenue Securities LLC now owns 8,914 shares of the medical device company's stock worth $321,000 after acquiring an additional 2,286 shares in the last quarter. Janney Montgomery Scott LLC increased its stake in Tandem Diabetes Care by 17.1% in the fourth quarter. Janney Montgomery Scott LLC now owns 30,240 shares of the medical device company's stock valued at $1,089,000 after purchasing an additional 4,412 shares during the last quarter. Stonehage Fleming Financial Services Holdings Ltd acquired a new stake in Tandem Diabetes Care during the fourth quarter worth approximately $92,000. KBC Group NV lifted its position in shares of Tandem Diabetes Care by 41.5% during the 4th quarter. KBC Group NV now owns 192,479 shares of the medical device company's stock worth $6,933,000 after buying an additional 56,461 shares during the last quarter. Finally, JB Capital LLC boosted its holdings in shares of Tandem Diabetes Care by 16.3% in the 4th quarter. JB Capital LLC now owns 39,213 shares of the medical device company's stock valued at $1,412,000 after buying an additional 5,484 shares in the last quarter.

Insiders Place Their Bets

In related news, COO Jean-Claude Kyrillos acquired 10,538 shares of the business's stock in a transaction dated Friday, March 7th. The shares were acquired at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the acquisition, the chief operating officer now directly owns 10,538 shares in the company, valued at approximately $190,948.56. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.90% of the stock is owned by corporate insiders.

Tandem Diabetes Care Trading Up 3.7%

TNDM stock traded up $0.76 during midday trading on Tuesday, hitting $21.48. The stock had a trading volume of 1,448,510 shares, compared to its average volume of 1,487,141. The company's 50-day moving average price is $19.41 and its 200 day moving average price is $27.31. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The firm has a market cap of $1.43 billion, a PE ratio of -11.13 and a beta of 1.47. Tandem Diabetes Care, Inc. has a 12-month low of $15.75 and a 12-month high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). The business had revenue of $234.42 million during the quarter, compared to analysts' expectations of $220.19 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. Tandem Diabetes Care's revenue for the quarter was up 22.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.65) EPS. On average, equities research analysts predict that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wells Fargo & Company decreased their price objective on Tandem Diabetes Care from $22.00 to $20.00 and set an "equal weight" rating for the company in a report on Thursday, May 1st. The Goldman Sachs Group decreased their price target on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Barclays lowered their price objective on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Citigroup upped their price target on shares of Tandem Diabetes Care from $20.00 to $24.00 and gave the stock a "neutral" rating in a research note on Thursday, May 22nd. Finally, Sanford C. Bernstein downgraded shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and cut their price target for the company from $35.00 to $25.00 in a report on Friday, February 28th. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $37.47.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.